Angiogenesis in breast cancer: insights and innovations.
Angiogenesis
Biomarkers
Breast cancer
Clinical implications
Imaging techniques
Personalized medicine
Resistance mechanisms
Therapeutic approaches
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
received:
13
04
2024
accepted:
19
07
2024
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
This review explores the pivotal role of angiogenesis in breast cancer progression and treatment. It covers biomarkers, imaging techniques, therapeutic approaches, resistance mechanisms, and clinical implications. Key topics include Vascular Endothelial Growth Factors, angiopoietins, microRNA signatures, and circulating endothelial cells as biomarkers, along with Magnetic Resonance Imaging, Computed Tomography Angiography, Ultrasound, and Positron Emission Tomography for imaging. Therapeutic strategies targeting VEGF, tyrosine kinase inhibitors, and the intersection of angiogenesis with immunotherapy are discussed. Challenges such as resistance mechanisms and personalized medicine approaches are addressed. Clinical implications, prognostic value, and the future direction of angiogenesis-targeted therapies are highlighted. The article concludes with reflections on the transformative potential of understanding angiogenesis.
Identifiants
pubmed: 39105831
doi: 10.1007/s10238-024-01446-5
pii: 10.1007/s10238-024-01446-5
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Informations de copyright
© 2024. The Author(s).
Références
Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6.
doi: 10.1056/NEJM197111182852108
pubmed: 4938153
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell. 1996;86(3):353–64.
doi: 10.1016/S0092-8674(00)80108-7
pubmed: 8756718
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–74.
doi: 10.1038/nature04483
pubmed: 16355214
Folkman J. Role of angiogenesis in tumour growth and metastasis. Semin Oncol. 2002;29(6 Suppl 16):15–8.
doi: 10.1053/sonc.2002.37263
pubmed: 12516034
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.
doi: 10.1038/nature10144
pubmed: 21593862
pmcid: 4049445
Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931–4.
doi: 10.1016/S0021-9258(19)49853-0
pubmed: 1375931
Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. 2005;94:209–31.
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603.
doi: 10.1038/nrc2442
pubmed: 18650835
pmcid: 2874834
Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl. 3):4–10.
doi: 10.1159/000088478
pubmed: 16301830
Jain RK. Normalization of tumour vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
doi: 10.1126/science.1104819
pubmed: 15637262
Bergers G, Benjamin LE. Tumourigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–10.
doi: 10.1038/nrc1093
pubmed: 12778130
Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417–27.
doi: 10.1038/nrd3455
pubmed: 21629292
Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399–408.
doi: 10.1016/j.cell.2012.01.021
pubmed: 22304911
pmcid: 3437543
Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001;106(4):148–56.
doi: 10.1159/000046610
pubmed: 11815711
Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer. 2002;2(11):826–35.
doi: 10.1038/nrc925
pubmed: 12415253
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–76.
doi: 10.1038/nm0603-669
pubmed: 12778165
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55–60.
doi: 10.1126/science.277.5322.55
pubmed: 9204896
Kerbel RS. Tumour angiogenesis. N Engl J Med. 2008;358(19):2039–49.
doi: 10.1056/NEJMra0706596
pubmed: 18463380
pmcid: 4542009
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Brown PO. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
doi: 10.1038/35021093
pubmed: 10963602